Araştırma Makalesi

COVID-19'lu Gebelerde Bazı Biyokimyasal ve Tam Kan Sayımı Parametrelerinin Değerlendirilmesi

Cilt: 63 Sayı: 2 10 Haziran 2024
PDF İndir
EN TR

Evaluation of Some Biochemical and Complete Blood Count Parameters in Pregnant Women with COVID-19

Abstract

Aim: Prediction of severity of COVID 19 infection in pregnant population is very important to management. The aim of this study was to investigate the relationship between COVID 19 infection severity and routine hematologic/biochemical laboratory tests. Material and Method: In this retrospective study the hematologic parameters of pregnant women with COVID 19 were investigated. The patients were allocated into 5 subgroups as asymptomatic, mild, moderate, severe and critical. Presenting symptoms were identified. Laboratory test results detected at the first admission were compared between groups. Results: A total of 343 patients were included in the study. The most common symptoms were cough (n=74, %21.6) and fatigue (n=46, %13.4). Statistically significant differences observed at following parameters. The mean Hb level was lower (p=0.001) and WBC, neutrophil, AST, ALT, GGT, LDH, direct bilirubin and total bilirubin levels were higher in critical group (p=, 0.005, 0.001, 0.000, 0.015, 0.000, 0.000, 0.000, 0.007 respectively). The mean lymphocyte and monocytes levels in the severe group were lower (p=0.000, 0.01, respectively). Furthermore, the mean eosinophil levels in the asymptomatic group was higher (p=0.002). Conclusion Low Hb, lymphocyte, monocyte, eosinophil levels and high WBC, neutrophil, ALT, AST, GGT, total bilirubin and LDH levels are associated with more severe disease. Monitoring of these tests may provide guidance for the prediction of the severity of the COVID 19 infection among pregnant women. Key Words: Complete Blood Count, COVID 19, laboratory, pregnancy, symptom, Conclusion Low Hb, lymphocyte, monocyte, eosinophil levels and high WBC, neutrophil, ALT, AST, GGT, total bilirubin and LDH levels are associated with more severe disease. Monitoring of these tests may provide guidance for the prediction of the severity of the COVID 19 infection among pregnant women.

Keywords

Kaynakça

  1. WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: https://covid19.who.int/
  2. Male V. SARS-CoV-2 infection and COVID-19 vaccination in pregnancy. Nature review Immunology. 2022; 22(5), 277–82. https://doi.org/10.1038/s41577-022-00703-6
  3. Aslan MM, Hilal U, Köse O, Cevrioğlu S, Özden S. (2020). COVID-19 ve Gebelik. Journal of Biotechnology and Strategic Health Research, 4, 10-13.
  4. Rasmussen SA, Jamieson DJ. COVID-19 and Pregnancy. Infectious disease clinics of North America. 2022; 36(2), 423–33. https://doi.org/10.1016/j.idc.2022.01.002
  5. Halk Saglıgı Genel Mudurlugu. COVID-19 (SARS-CoV-2 Enfeksiyonu) Rehberi. Bilim Kurulu Çalısması. Ankara: Saglık Bakanlıgı.https://covid19bilgi.saglik.gov. tr/depo/rehberler/ COVID-19_Rehberi.pdf
  6. Sari T. (2021). Gebelikte COVID-19 hastalığının takip ve tedavisi. Turkish Journal of Clinics and Laboratory, 12(4), 473-6.
  7. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra Set al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Le infezioni in medicina. 2021; 29(1), 20–36.
  8. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. Acta obstetricia et gynecologica Scandinavica 2020; 99(7), 823–29.https://doi.org/10.1111/aogs.13867

Ayrıntılar

Birincil Dil

İngilizce

Konular

Kadın Hastalıkları ve Doğum

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

10 Haziran 2024

Gönderilme Tarihi

5 Ağustos 2023

Kabul Tarihi

1 Kasım 2023

Yayımlandığı Sayı

Yıl 1970 Cilt: 63 Sayı: 2

Kaynak Göster

Vancouver
1.Mehmet Kağıtcı, İlkay Bahçeci, Zihni Acar Yazıcı, Hizir Kazdal, Deniz Dereci Delibaş, Nalan Kuruca, Bülent Yılmaz. Evaluation of Some Biochemical and Complete Blood Count Parameters in Pregnant Women with COVID-19. ETD. 01 Haziran 2024;63(2):223-9. doi:10.19161/etd.1337602

Ege Tıp Dergisi, makalelerin Atıf-Gayri Ticari-Aynı Lisansla Paylaş 4.0 Uluslararası (CC BY-NC-SA 4.0) lisansına uygun bir şekilde paylaşılmasına izin verir.